I2Pure Expands Leadership and Scientific Team to Support Molecular Iodine Manufacturing and Research Growth
I2Pure Corp., a biotechnology company focused on patented molecular iodine (I₂) technology for antimicrobial and antiseptic applications, has announced the addition of three experienced professionals to its expanding team. The appointments strengthen the company’s manufacturing, supply chain, quality engineering and biomaterials research capabilities as I2Pure continues to develop and scale its molecular iodine platform.
Christopher Wilkes has joined the company as Vice President of Production & Supply Chain, while Nichole Coggins has been appointed Director, Quality Engineering. Both executives will be based at I2Pure’s manufacturing facility in Asheville, North Carolina. Maggie Engert has joined the company as a Biomaterials Scientist and will be based at I2Pure’s research and development laboratory in Manassas, Virginia.
The appointments come at a time when I2Pure is expanding its manufacturing operations and advancing scientific research around its molecular iodine technology. The company said the new team members bring extensive experience spanning regulated manufacturing, supply chain management, quality systems, medical devices, biologics, biodefense, public health and laboratory research.
According to I2Pure, the combined expertise of the three new hires is expected to support the company as it scales its operations and continues research into potential applications of its molecular iodine platform.
“These are three phenomenal people bringing phenomenal talent to our team,” said Jeff Jochims, CEO of I2Pure. “We’re fortunate to be able to attract this level of talent to our expanding team, and excited to welcome Chris, Nicki and Maggie to I2Pure!”
Strengthening Manufacturing and Supply Chain Operations
Wilkes joins I2Pure with more than 25 years of leadership experience across regulated manufacturing, supply chain and commercial operations within the life sciences sector. In his new position as Vice President of Production & Supply Chain, he will be responsible for leading the company’s manufacturing and supply chain strategy.
His background includes more than 15 years with Thermo Fisher Scientific, where he progressed through a series of increasingly senior positions, beginning as a research scientist and ultimately becoming Vice President and General Manager of a global Good Manufacturing Practice (GMP) business with more than $350 million in value.
The experience provides Wilkes with a combination of scientific, operational and commercial expertise that I2Pure expects will be important as the company expands its manufacturing activities.
Regulated manufacturing requires companies to maintain consistent production processes, supply chain reliability, quality controls and documentation while meeting applicable regulatory expectations. For a biotechnology company developing antimicrobial and antiseptic technologies, the ability to translate scientific development into scalable and controlled manufacturing processes can be an important component of commercial growth.
Wilkes will therefore play a central role in coordinating I2Pure’s production capabilities with its broader business and technology development plans.
His professional background also includes a strong scientific foundation. Wilkes holds a Bachelor of Science degree in Biochemistry and a Master of Science degree in Molecular Biology, both from the University of Georgia.
The combination of molecular biology training and extensive life sciences manufacturing leadership is expected to support his responsibilities across I2Pure’s production and supply chain activities.
Quality Engineering Expertise Added to I2Pure Team
Coggins joins I2Pure as Director, Quality Engineering, bringing more than two decades of experience in quality and regulatory leadership across the medical device and biologics industries.
Her career includes an extensive tenure with Owens & Minor, where she developed experience in quality management and regulatory compliance. Coggins has worked on initiatives focused on strengthening Quality Management Systems (QMS) and supporting compliance with major regulatory and industry standards.
Her experience includes work involving U.S. Food and Drug Administration (FDA) requirements, ISO 13485 standards for medical device quality management systems and European Union Medical Device Regulation (EU MDR) requirements.
For a biotechnology company expanding manufacturing operations, quality engineering represents an important element of maintaining consistent processes and preparing products and operations for regulatory requirements. Quality systems can influence everything from manufacturing procedures and documentation to supplier management, process controls and product release.
Coggins is expected to contribute her experience to I2Pure’s efforts to strengthen its quality infrastructure while supporting the company’s broader operational growth.
Her background also includes leading quality transformation initiatives across global operations. Such experience can be particularly relevant as companies move from smaller-scale research and development activities toward more structured manufacturing and commercialization processes.
Coggins earned a Bachelor of Science degree from Mars Hill University in North Carolina.
Her appointment alongside Wilkes creates an expanded leadership structure covering both production and quality functions at I2Pure’s Asheville manufacturing facility.
Biomaterials Scientist Expands R&D Capabilities
At I2Pure’s Manassas, Virginia R&D laboratory, Engert joins the organization as a Biomaterials Scientist. Her background includes experience spanning biodefense, public health and laboratory research.
Engert holds a Master of Science degree in Biodefense from George Mason University, where her studies focused on health security preparedness, biosurveillance and emerging biological threats. She also earned a Bachelor of Science degree in Public Health from the University of Nevada, Reno.
Her scientific and public health background adds another dimension to I2Pure’s research team as the company continues investigating applications of molecular iodine technology.
Biomaterials research can involve examining interactions between materials and biological systems and can support the development and evaluation of technologies intended for use in healthcare and related applications. At I2Pure, Engert will contribute to the company’s research activities involving its molecular iodine platform.
Her experience in biodefense and emerging biological threats also provides a scientific perspective relevant to antimicrobial research, an area closely associated with I2Pure’s technology focus.
Focus on Molecular Iodine Technology
I2Pure is developing technologies based on molecular iodine, also known as I₂, for antimicrobial and antiseptic applications. The company describes its platform as being supported by patented molecular iodine technology.
Iodine has a long history of use in antimicrobial and antiseptic applications, but molecular iodine technologies can involve specific formulation, delivery and stability considerations. I2Pure’s research and development efforts are focused on its proprietary technology platform and potential applications derived from it.
As the company advances its platform, expanding both its scientific and operational teams can help connect laboratory research with manufacturing and quality requirements.
The appointments of Wilkes, Coggins and Engert represent an expansion across three complementary areas. Wilkes brings manufacturing and supply chain leadership, Coggins adds quality and regulatory expertise, and Engert strengthens the scientific research organization.
Together, these capabilities can help I2Pure address the operational requirements associated with scaling biotechnology products while continuing to conduct research and development.
Building Infrastructure for Continued Growth
The hiring announcements come as I2Pure works to expand its manufacturing operations and scientific research. For emerging biotechnology companies, scaling operations requires more than increasing production capacity. Companies also need experienced leadership capable of managing quality systems, supply networks, regulatory requirements and research programs.
The addition of Wilkes is aimed at strengthening the production and supply chain side of the organization. His experience managing a large GMP business gives I2Pure access to expertise in regulated manufacturing environments and commercial operations.
Coggins’ appointment adds dedicated quality engineering leadership. Her experience with FDA, ISO 13485 and EU MDR requirements provides expertise relevant to organizations operating in highly regulated healthcare markets.
At the same time, Engert’s appointment expands the scientific team working at I2Pure’s Manassas R&D facility. Her education and professional background in biodefense and public health complement the company’s focus on antimicrobial and antiseptic technologies.
The combination illustrates I2Pure’s effort to build capabilities across the full development pathway, from laboratory research through manufacturing and quality management.
Supporting Future Development
The company’s expansion comes as interest continues in technologies designed to address microbial contamination and infection-control challenges across healthcare and other environments. Antimicrobial and antiseptic technologies can have applications in a variety of settings, depending on product design, regulatory status and demonstrated performance.
For I2Pure, continued investment in its molecular iodine platform will require scientific development alongside operational execution. The company’s latest appointments are intended to provide additional expertise as it progresses those activities.
Jochims said the company was pleased to attract experienced professionals to its growing organization and emphasized the contribution that the new hires are expected to make.
The appointments also position I2Pure to further develop its infrastructure in North Carolina and Virginia. The Asheville facility will benefit from leadership in production, supply chain and quality engineering, while the Manassas R&D laboratory gains additional scientific expertise through Engert’s appointment.
As the company continues to advance its molecular iodine technology, maintaining strong coordination between research, manufacturing and quality functions will be important to its development strategy. Research findings must ultimately be translated into controlled and reproducible processes, while quality systems must evolve alongside manufacturing activities and applicable regulatory requirements.
I2Pure’s latest team expansion therefore represents more than the addition of three individual employees. It reflects the company’s broader effort to strengthen the organizational capabilities needed to support its patented molecular iodine platform.
With Wilkes leading production and supply chain strategy, Coggins overseeing quality engineering and Engert contributing to biomaterials research, I2Pure has expanded expertise across key areas of its business. The company expects the new team members to support its ongoing manufacturing scale-up and scientific research as it continues developing antimicrobial and antiseptic applications based on molecular iodine technology.
About I2Pure
I2Pure is an iodine technology company dedicated to advancing health and biosafety through its patented, non-toxic molecular iodine solutions. I2Pure’s mission is to prevent pathogenic threats to the world. Our technology can be utilized for countless applications across healthcare, industrial biosafety, consumer products, and food processing. The platform technology can be delivered directly or through carriers via solutions, nano particles, polymers, and coatings.